Perceptive Advisors Reports 4.6% Stake in CytomX Therapeutics, Inc. (CTMX)

Perceptive Advisors LLC, along with Joseph Edelman and the Perceptive Life Sciences Master Fund, Ltd., filed a Schedule 13G/A on May 15, 2026, regarding their holdings in CytomX Therapeutics, Inc. (CTMX). The filing reveals that the reporting persons collectively hold 10,098,824 shares of Common Stock, representing a 4.6% ownership stake in the company. This position marks an increase from the previously reported 0.0% ownership. The shares are held directly by the Master Fund, with Perceptive Advisors serving as the investment manager and Joseph Edelman acting as the managing member of Perceptive Advisors. Consequently, both Perceptive Advisors and Mr. Edelman may be deemed to share beneficial ownership of the securities. The calculation of the ownership percentage is based on 217,702,919 shares outstanding as of April 30, 2026. The filing indicates that the securities were not acquired for the purpose of changing or influencing the control of the issuer.